Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 3;14(1):217.
doi: 10.3390/cancers14010217.

The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy

Affiliations
Review

The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy

Niklas Sturm et al. Cancers (Basel). .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is still difficult to treat due to insufficient methods for early diagnosis and prediction of therapy response. Furthermore, surveillance after curatively intended surgery lacks adequate methods for timely detection of recurrence. Therefore, several molecules have been analyzed as predictors of recurrence or early detection of PDAC. Enhanced understanding of molecular tumorigenesis and treatment response triggered the identification of novel biomarkers as predictors for response to conventional chemotherapy or targeted therapy. In conclusion, progress has been made especially in the prediction of therapy response with biomarkers. The use of molecules for early detection and recurrence of PDAC is still at an early stage, but there are promising approaches in noninvasive biomarkers, composite panels and scores that can already ameliorate the current clinical practice. The present review summarizes the current state of research on biomarkers for diagnosis and therapy of pancreatic cancer.

Keywords: biomarker; molecular diagnostics; pancreatic ductal adenocarcinoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

L.P. travel expenses: Ipsen, consulting/advisory role: Servier, AstraZeneca. N.S. and T.J.E. declare no conflict of interest.

Figures

Figure 1
Figure 1
Established biomarkers to direct decision making in pancreatic cancer. Summary of biomarkers which should be considered for therapy decision in PDAC based on sufficient clinical evidence. For advanced PDAC, NTRK, KRASG12C, germline BRCA1/2, and MSI/dMMR should be tested for targeted therapy. To avoid excessive toxicity, DPD-mutation should be evaluated before therapy with a fluoropyrimidine. CA19-9 should be tested regularly before adjuvant therapy and can guide therapy in advanced disease. (gBRCA1/2 = germline BRCA1/2; MSI = microsatellite instability; dMMR = deficient mismatch repair; DPD = dihydropyrimidine dehydrogenase).

Similar articles

Cited by

References

    1. Ushio J., Kanno A., Ikeda E., Ando K., Nagai H., Miwata T., Kawasaki Y., Tada Y., Yokoyama K., Numao N., et al. Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics. 2021;11:562. doi: 10.3390/diagnostics11030562. - DOI - PMC - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Huang J., Lok V., Ngai C.H., Zhang L., Yuan J., Lao X.Q., Ng K., Chong C., Zheng Z.-J., Wong M.C. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160:744–754. doi: 10.1053/j.gastro.2020.10.007. - DOI - PubMed
    1. Maisonneuve P., Lowenfels A.B. Risk factors for pancreatic cancer: A summary review of meta-analytical studies. Int. J. Epidemiol. 2014;44:186–198. doi: 10.1093/ije/dyu240. - DOI - PubMed
    1. Gupta S., Wang F., Holly E.A., Bracci P.M. Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: A population-based study. Cancer Causes Control. 2010;21:1047–1059. doi: 10.1007/s10552-010-9533-6. - DOI - PMC - PubMed

LinkOut - more resources

-